2026 NPPES data Glaucoma Specialist (Ophthalmology) Physician NPI 1568451797 M.D.
Verify on CMS →

PETER CHANG, M.D.

Glaucoma Specialist (Ophthalmology) Physician in HOUSTON, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
5K
Medicare Part D claims · 920 beneficiaries · Glaucoma Specialist (Ophthalmology) Physician avg: 3K
MIPS score
84.059/100
▲ 1 pts above national avg 83.1 · [object Object]
Industry payments
$115.1K
205 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

PETER CHANG, M.D. reported a CMS MIPS final score of 84.059/100 — above the 83.1 national average — and filed 5,095 Medicare Part D claims in 2023.

84.059/100
MIPS score · +1 vs avg
5K
Part D claims, 2023
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

PETER CHANG, M.D.'s MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

84 45th percentile higher than 45% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). This entry sits in this band. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

PETER CHANG, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about PETER CHANG, M.D.?

Near national average

NPI registry status

Active

Issued 10/20/2005

NPI 1568451797

Primary specialty

Glaucoma Specialist (Ophthalmology) Physician

Rare

354 US NPIs in this specialty

Medicare Part D claims

5,095 72% vs specialty avg

2023 prescription claims

Specialty avg: 2,962

MIPS final score

84.059/100 0.9590000000000032% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Texas

How Glaucoma Specialist (Ophthalmology) Physician compares to other specialties among Texas providers

Texas providers

Glaucoma Specialist (Ophthalmology) Physician share within Texas

1. Glaucoma Specialist (Ophthalmology) Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Glaucoma Specialist (Ophthalmology) Physician share within Texas

Medicare quality performance — MIPS

PETER CHANG, M.D.'s 2023 MIPS final score plotted against the Glaucoma Specialist (Ophthalmology) Physician national average

Near national average
MIPS Final Score
84.059/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Glaucoma Specialist (Ophthalmology) Physician) — 84.059/100 vs national avg 83.1

0%100%National avg83%84.1%
MIPS final score (Glaucoma Specialist (Ophthalmology) Physician) — 84.059/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

PETER CHANG, M.D. appears in the CMS NPPES registry as a Glaucoma Specialist (Ophthalmology) Physician provider holding M.D. credentials at 1977 BUTLER BLVD, HOUSTON, TX, 77030, with a listed phone of (713) 798-6100. NPI 1568451797 was issued on 10/20/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CHANG most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 5,095 prescription claims written by this provider, covering 920 Medicare beneficiaries and totaling roughly $1.0 million in drug spend. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 84.059/100 for the 2023 performance year (Quality 84.4904, Cost 54.3968), compared with the national average of 83.1.

Glaucoma Specialist (Ophthalmology) Physician is a narrow specialty nationwide, with 354 enrolled providers across 42 states and an average of 2,962 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1977 BUTLER BLVD
HOUSTON, TX 77030

Provider Details

NPI 1568451797
Specialty Glaucoma Specialist (Ophthalmology) Physician
Credentials M.D.
Gender Male
NPI Issued 10/20/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

84.059
Final Score
Avg: 83.1
84.4904
Quality
54.3968
Cost

Reporting: Group practice

Hospital and facility affiliations

Facilities where PETER CHANG, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

BAYLOR COLLEGE OF MEDICINE
HOUSTON, TX
BAYLOR COLLEGE OF MEDICINE
HOUSTON, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PETER CHANG, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$115.1K

Largest payer

ABBVIE INC.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to PETER CHANG, M.D.. To verify PETER CHANG, M.D.'s current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

5,095
Total Claims
$1.0M
Total Drug Cost
920
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
9,941
Total Day Supply
288,461
Generic Drug Cost
$231K
Antibiotic Claims
96

Patient Demographics

Average Patient Age
75.6 years
Avg HCC Risk Score
1.31
Gender Split
54% female / 46% male
Age Distribution
<65: 52, 65-74: 357, 75-84: 372, 85+: 139

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What PETER CHANG, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Latanoprost
738
Dorzolamide-Timolol
Dorzolamide Hcl/Timolol Maleat
627
Timolol Maleate
392
Combigan
Brimonidine Tartrate/Timolol
323
Brimonidine Tartrate
254
Prednisolone Acetate
226
Travoprost
190
Moxifloxacin
Moxifloxacin Hcl
172
Lumigan
Bimatoprost
157
Brimonidine Tartrate-Timolol
Brimonidine Tartrate/Timolol
144

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Glaucoma Specialist (Ophthalmology) Physician Overview

How PETER CHANG, M.D. fits within the Glaucoma Specialist (Ophthalmology) Physician landscape nationally.

354
Glaucoma Specialist (Ophthalmology) Physician Providers in US
42
States with Glaucoma Specialist (Ophthalmology) Physician
2,962
Avg Claims per Provider

PETER CHANG, M.D.'s 5,095 claims are above the specialty average of 2,962.

Nearby Glaucoma Specialist (Ophthalmology) Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as CHANG.

Compare Glaucoma Specialist (Ophthalmology) Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is PETER CHANG, M.D.'s specialty?
PETER CHANG, M.D. specializes in Glaucoma Specialist (Ophthalmology) Physician and practices in HOUSTON, Texas. Credentials: M.D..
How much does PETER CHANG, M.D. prescribe under Medicare Part D?
In 2023, PETER CHANG, M.D. wrote 5,095 Medicare Part D claims totaling $1.0M in drug costs for 920 beneficiaries.
What is PETER CHANG, M.D.'s Medicare quality score?
PETER CHANG, M.D. has a CMS MIPS Final Score of 84.059/100 (Quality: 84.4904, Cost: 54.3968). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is PETER CHANG, M.D. located?
PETER CHANG, M.D. is located at 1977 BUTLER BLVD, HOUSTON, TX, 77030. Phone: (713) 798-6100.
What is PETER CHANG, M.D.'s NPI number?
PETER CHANG, M.D.'s National Provider Identifier (NPI) is 1568451797, issued on 10/20/2005.
How many Glaucoma Specialist (Ophthalmology) Physician providers are there in the US?
There are 354 Glaucoma Specialist (Ophthalmology) Physician providers across 42 states in the US. The average Glaucoma Specialist (Ophthalmology) Physician provider writes 2,962 Medicare Part D claims per year.
What drugs does PETER CHANG, M.D. prescribe most often?
Based on 2023 Medicare Part D data, PETER CHANG, M.D.'s most frequently prescribed drugs include Latanoprost, Dorzolamide-Timolol, Timolol Maleate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does PETER CHANG, M.D. accept Medicare?
PETER CHANG, M.D. appears in CMS Medicare data with 5,095 Part D claims and 920 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify PETER CHANG, M.D.'s credentials?
PETER CHANG, M.D.'s NPI is 1568451797 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology